- P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS
-
The present disclosure provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R1-R7 are defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2X3 or P2X2/3 receptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient. In another embodiment, these compounds are useful for treating respiratory dysfunction in patients by administering one or more of the compounds to a patient.
- -
-
Paragraph 0361-0364
(2018/04/17)
-
- A study and identification of potential by-products of sibutramine
-
In the synthesis and process development of sibutramine (9), the isolation and characterization of two potential by-products namely heptane dinitriles (4a-b) and bis-cyclobutyl alkylamine (10) have been studied. The key steps in the synthesis of sibutramine which have contributed to the formation of above by-products are cycloalkylation of 4-chlorophenyl acetonitrile (1) and tandem Grignard reduction on 1-(4-chlorophenyl)cyclobutyl carbonitrile (3).
- Reddy, G. Om,Sarma,Chandrasekhar,Babu, J. Moses,Prasad,Raju, C.M. Haricharan
-
p. 488 - 492
(2013/09/08)
-
- Multidrug resistance modifying dithianes
-
Compounds of the formula STR1 wherein R is a residue of the formula STR2 and R1, R2, R3, R4, R5, R6, R7, X, Y and Z are as described, with the exception of rac-N-(3,4-dimethoxyphenethyl)-2-(3,4-dimethoxyphenyl)-β,N-dimethyl-m-dithiane-2-propanamine, as well as their acid addition salts, in particular for use in eliminating cytostatic resistance in tumor treatment and chloroquine resistance in malaria.
- -
-
-